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ABSTRACT
Objectives: The objectives of this study were to evaluate cognitive profile in patients with chronic kidney disease (CKD) pre-dialysis and post-dialysis, 
to assess the severity of cognitive impairment in patients with kidney disease before and after dialysis, and to determine the association of cognitive 
impairment in relation to dialysis.
Methods: A total of 59 patients were recruited with CKD Stage V on dialysis for >6 months. Cognitive function of the patient was assessed by Montreal 
Cognitive Assessment test scale method for three intervals (before dialysis and two intervals post-dialysis), and the incidence of impairment was 
analyzed using one-way ANOVA variance test.
Results: Among the 59 patients, there were 13 patients with the age of 18–33 years (22.033%), 11 patients with from age 34 to 49 years (18.64%), 
21 patients at the age of 50–65 years (35.59%), and 15 patients around 66–80 years (25.42%). From the above categories, population with the age of 
50–65 years is at maximum affected by CKD. Among the 59 patients, 24 patients (40.677%) are male and 35 patients (59.33%) are female. There was 
a mild significant difference seen in cognitive functioning between pre-dialysis and post-dialysis (p≤0.02).
Conclusion: It was found that patients with CKD had mild-to-moderate cognitive dysfunction due to morbidities associated with CKD. In this study, 
significant differences of cognitive function result in CKD patients and the severity of cognitive impairment was associated with the severity of the 
kidney disease, which improved with dialysis. Finally, our study suggests that cognitive performance was improved after initiation of dialysis and that 
further management through medications could provide a better outcome in cognitive performance.
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INTRODUCTION
The kidney disease improving outcomes (2012) clinical practice 
guidelines define chronic kidney disease (CKD) as persistent 
abnormalities to renal morphology and function for a period of 
> 3 months with due to implications for health [1,2]. Classification of 
CKD stages is made on the basis of glomerular filtration rate (GFR), 
albumin, and etiology. Characterized by a GFR of <15 ml/min/1.73 m2, 
end-stage renal disease (ESRD) remains the final stage of CKD in which 
hemodialysis and renal transplant are the therapeutic options for uremic 
clearance and restoration of renal function, respectively [3,4]. Type 2 
diabetes mellitus and hypertension have evolved as the major cause 
of ESRD due to the widespread global pandemic of the disease [5,6]. 
Outcomes of CKD include not only kidney failure but also complications 
of decreased kidney function, cardiovascular disease, and loss of 
cognitive function [7,8]. The current evidence suggests that some of 
these adverse outcomes can be prevented or delayed by early detection 
and treatment [9-11].
METHODS
A longitudinal study of 6 months was carried out. This study was 
carried out multispecialty hospital, Chennai, at dialysis unit in the 
nephrology department. A total of 60 patients under single group 
were studied. All the CKD patients of either gender of age >18 years 
undergoing dialysis were taken for the study. Inclusion criteria include 
patients with CKD undergoing dialysis. Exclusion criteria, patients with 
other psychotic disorders such as schizophrenia and Alzheimer’s were 
excluded, pregnant and lactating women were excluded, and patients 
not willing to participate were also exclude from the study. Approval 
of study protocol by the institutional ethical committee was obtained 
before commencement. Patients with CKD and other study criteria are 
enrolled in the study. Clinical information relevant for the study such as 
medication charts, previous medical problems, and current treatment 
plan of dialysis was obtained from the patient; written consent was 
obtained from all the patients. The patients enrolled in the study are 
assessed for the cognition function test according to widely accepted 
testing categories (orientation and attention, perception, memory, 
language, and executive functions) using Montreal Cognitive Assessment 
(MOCA) scale. The cognitive functions are assessed at baseline (before 
dialysis) and monitored at regular intervals. The cognition testing will 
be assessed 3 times - at baseline, after 2 months, and at the end of the 
6th month. The cognitive function will be determined by comparing the 
scores obtained by the individual in all the three intervals according 
to the MOCA scale scoring. Statistical analysis was carried out using 
GraphPad Prism 7. Descriptive summary statistics were presented as 
mean and S.D for parametric data and median and quartile for non-
parametric data. The cognitive impairment between all the three 
intervals (before and after dialysis) was compared and analyzed using 
one-way ANOVA analysis of variance, ethical committee approval No. 
VISTAS-SPS/IEC/II/2017/11.
RESULTS
The study included 59 patients in which all were cases diagnosed with 
CKD on dialysis. The results of study showed that 59 patients with CKD 
in various age groups. Among the 59 patients, there were 13 patients 
with the age of 18–33 years (22.033%), 11 patients with from age 34 to 
49 years (18.64%), 21 patients at the age of 50–65 years (35.59%), and 
15 patients around 66–80 years (25.42%). From the above categories, 
population with the age of 50–65 years is at maximum affected by CKD. 
Among the 59 patients, 24 patients (40.677%) are male and 35 patients 
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(59.33%) are female. The various baseline characteristics in CKD 
patients. It was noted that all the parameters including hemoglobin, 
urea, and creatinine showed drastic variations from normal levels and 
this relates to the disease factor. After analyzing between all the three 
intervals of cognitive testing, there was statistically a mild significance 
observed in cognitive function. Table 5 shows the extent and severity of 
impairment before dialysis to which the individuals are affected and the 
level of change in impairment post-dialysis period (Tables 1-4).
CONCLUSION
It was found that patients with CKD had mild-to-moderate cognitive 
dysfunction due to morbidities associated with CKD. In this study, 
significant difference of cognitive function results in CKD patients, and 
the severity of cognitive impairment was associated with the severity 
of the kidney disease, which improved with dialysis. Finally, our study 
suggests that cognitive performance was improved after initiation 
of dialysis and that further management through medications could 
provide a better outcome in cognitive performance.
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No impairment 15 27 36
Mild impairment 26 21 14
Moderate impairment 10 11 9 
Severe impairment 0 0 0
Total points: 30, No impairment: ≥26, Mild impairment: 19–23, Moderate 
impairment: 10–18, Severe impairment: ≤9
Gender Number of patients (n=59) Percentage of patients (%)
Male 24 40.677
Female 35 59.33





Baseline characteristics Number of patients (n=59)
Systolic BP (mmHg) 138.5±14.15
Diastolic BP (mmHg) 83 (2.57)
Blood urea (mg/dl) 90.78±38.14
Serum creatinine (mg/dl) 6.593±2.497
Sodium (mmol/l) 138.4±5.527
Potassium (mmol/l) 4.9 (1.2)
Hemoglobin (g/dl) 10.09±1.598
*Parametric data presented as mean and S.D and non-parametric as median and 
quartile, BP: Blood pressure, CKD: Chronic kidney disease
Cognitive function ANOVA test value p value
Before and after dialysis 7.463 0.0240
CKD: Chronic kidney diseaseFig. 1: One-way ANOVA data
Table 4: Analysis of cognitive performance in CKD patients
Table 3: Baseline characteristics in CKD patients
Table 2: Distribution based on age
Table 1: Distribution based on gender
Fig. 2: Cognitive scoring before and after dialysis
